The role of menopausal hormone therapy in osteoporosis

Climacteric

Volumn 10, Issue SUPPL. 2, 2007, Pages 71-73

  De Villiers, T ^a  

^a Panorama Mediclinic ^*  (South Africa)

Author keywords

Hormone therapy; Menopause; Osteoporosis

Indexed keywords

ALCOHOL; ALGESTONE; DROSPIRENONE; ESTRADIOL; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ALCOHOL CONSUMPTION; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; GYNECOLOGY; HEALTH HAZARD; HISTOLOGY; HORMONAL THERAPY; HORMONE ACTION; HUMAN; MAMMOGRAPHY; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; PROGNOSIS;

BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 34548856824     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701550341     Document Type: Conference Paper

References (12)

1. Lindsay R, Gallagher JC, Kleerekoper M, et al. Bone response to treatment with lower dosages of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005;4:372-9
2. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy and venous thromboembolism among postmenopausal women: the impact of the route of estrogen administration. Circulation 2005;22:3495-500
3. Birge SS. Editorial. Estrogen and stroke: a case for low-dose estrogen. Menopause 2006;13:719-20
4. The Women's Health Initiative Steering Committee. Effects of conjugated estrogen on postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
5. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. Arch Intern Med 2006;166:357-65
6. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006;15:35-44
7. Yates J, Barret-Connor E, Barlas S, et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004;103:440-6
8. Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone replacement therapy in healthy women have long-term prevention effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-31
9. Woo S-B, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61
10. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
11. Reginster J-Y, Abadie E, Delmas P, et al. Recommendations for an update of the current (2001) regulatory requirements for the registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and men. Osteoporos Int 2006;17:1-7
12. Executive Committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Climacteric 2004;7:8-11